The presence of hundreds of copies of mitochondrial DNA (mtDNA) in each human cell poses a challenge for the complete characterization of mtDNA genomes by conventional sequencing technologies 1 . Here we describe digital sequencing of mtDNA genomes with the use of massively parallel sequencing-bysynthesis approaches. Although the mtDNA of human cells is considered to be homogeneous, we found widespread heterogeneity (heteroplasmy) in the mtDNA of normal human cells. Moreover, the frequency of heteroplasmic variants varied considerably between different tissues in the same individual. In addition to the variants identified in normal tissues, cancer cells harboured further homoplasmic and heteroplasmic mutations that could also be detected in patient plasma. These studies provide insights into the nature and variability of mtDNA sequences and have implications for mitochondrial processes during embryogenesis, cancer biomarker development and forensic analysis. In particular, they demonstrate that individual humans are characterized by a complex mixture of related mitochondrial genotypes rather than a single genotype.
Mitochondria are crucial in many basic cellular processes, and as a result of its unique maternal inheritance pattern and relatively high mutation rate, mtDNA is often used in studies of evolutionary biology and population genetics. These same attributes, combined with the high copy number of mtDNA in cells, makes mtDNA a favoured substrate for forensic analysis 2 . In typical human cells, there are between 50 and hundreds of mitochondria per cell and five to ten copies of mtDNA per mitochondrion 1 . The presence of multiple copies of mtDNA per cell leaves open the possibility that all the copies are not identical. Many studies have shown that mtDNA is homoplasmic in normal cells; that is, all of the mtDNA copies are identical not only in an individual cell but also among cells. However, there is apparently a low level of heteroplasmy in the mtDNA of various species, including humans [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . To evaluate this issue further, we have used massively parallel sequencing-by-synthesis approaches to thoroughly characterize the mtDNA of normal and neoplastic human cells.
Two sets of PCR primers, each resulting in amplicons of about 650 base pairs (bp) in length, were designed to cover the mtDNA genome ( Fig. 1a ). Sequencing libraries for Illumina GAII made from the PCR products of normal colonic mucosa DNA (patient 1) yielded 8.5 million tags that matched the mitochondrial genome. Each mtDNA base was sequenced, on average, 16,700 times and fewer than 11 bases (0.07% of the 16,569 bp in the mtDNA genome) were represented fewer than 1,000 times ( Supplementary Fig. 1a ).
This high coverage permitted us to identify heteroplasmic variants even when they were relatively rare-theoretically, when present in as few as 1 per 10,000 mitochondrial genomes. However, errors that had accumulated during the PCR and sequencing steps limited the sensitivity achieved. Control libraries made from PCR products of nuclear DNA demonstrated that the average proportion of mutations per base was 0.058%, with a standard deviation of 0.057%, and no base was mutated at greater than 0.82% frequency (Supplementary Information). We therefore made the very conservative assumption that all variants present in excess of twice this value (1.6%) represented true heteroplasmies rather than sequencing artefacts. Using these criteria, we detected 28 homoplasmic alleles and 8 heteroplasmic alleles in this sample of normal colonic mucosa (patient 1). Homoplasmic alleles were defined as any allele not present in the standard mtDNA reference sequence of humans but present in more than 98.4% (that is, 100% 2 1.6%) of the mtDNA sequences analysed. All homoplasmic alleles identified in patient 1 had previously been identified in normal individuals. The less frequent (minor) alleles at the heteroplasmic sites represented 1.6-29.7% of the total alleles at that site (Table 1 ). All (100%) of these eight heteroplasmic alleles were listed as normal variants in mtDNA databases, whereas only 3,601 bases (21.7%) of the 16,569 bases in the mitochondrial genome are reported to have variants in the same databases (P , 0.01, x 2 ).
Two control experiments were performed to verify that these heteroplasmic allelic variants were not generated as a result of artefacts. First, we performed an independent PCR analysis of the mtDNA genome using nine pairs of primers (primer set PCR3 in Fig. 1a ) that produced longer PCR products and had been shown not to amplify homologous nuclear DNA sequences 15 . Sequencing of these PCR products on an Illumina GAII confirmed the identical 28 homoplasmic and heteroplasmic alleles at similar frequencies to those identified with the two other PCR primer sets (Table 1) . Second, we employed a capture-based approach for enrichment rather than a PCR-based approach (Fig. 1b) ; this yielded 3.4 million tags, and each mtDNA base was sequenced 7,300 times on average ( Supplementary Fig. 1b ). The homoplasmic and heteroplasmic alleles discovered with the PCR-based enrichment strategy were again observed (Table 1) .
To determine whether the relatively high number of heteroplasmic variants in this sample was unusual, we analysed nine additional samples of normal colorectal mucosae. Heteroplasmic allelic variants were observed in each of these additional samples, with an average of 28 homoplasmic and four heteroplasmic alleles per sample. The minor-allele frequencies of the heteroplasmic variants ranged from 1.6% to 43.6% ( Supplementary Table 1 ).
To test whether this relatively high level of heteroplasmy was specific to colorectal mucosa tissue, we studied ten tissues obtained from autopsy of a single individual. All homoplasmic alleles in one tissue were found to be homoplasmic in all other tissues. However the fraction and number of heteroplasmic variants varied from tissue to tissue. Each tissue harboured at least one heteroplasmic variant and four tissues harboured at least four heteroplasmic variants, each with minor allele frequencies of more than 1.6% ( Table 2 ). As a result of this variation, twice as many heteroplasmic alleles than homoplasmic alleles were observed in the tissues from an individual (14 and 7, respectively), the reverse of what was found in any single tissue such as normal colorectal mucosa.
One of the most tantalizing aspects of these data was that 5 of the 14 heteroplasmic variants were found in more than one tissue. For example, the most common heteroplasmic variant, at base 16093, was identified in all tissues but its allelic frequency varied from 7.4% to 90.9%. The variant at codon 72 was present in kidney and liver at 18.4% and 11.7% allelic frequencies, respectively, but was not detectable in eight other tissues ( Table 2 and Supplementary Figs 2 and 3 ).
To verify that this tissue-specific heteroplasmy was a general phenomenon, we analysed the mtDNA of five tissues from another individual (Supplementary Table 2 ). The same patterns were evident, with a high ratio of heteroplasmic to homoplasmic alleles (11:7) and variant frequencies differing by more than 100-fold between different tissues. As an independent test of the observed heteroplasmy, we determined the sequence of the most abundant variants by using conventional dyeterminator chemistry. Although not nearly as quantitative as the digital approach afforded by sequencing-by-synthesis approaches, the chromatograms confirmed the existence and relative extent of heteroplasmy in each case ( Supplementary Fig. 3 ).
There are three potential ways to explain the heteroplasmic variants observed here and in other studies 14, 16 . The first of these is paternal: heteroplasmic variants might represent mtDNA inherited from the father. The second is maternal: heteroplasmic variants might be inherited from the mother, with bottlenecks during embryonic development resulting in tissue-specific variations. The third is de novo: heteroplasmic variants might represent new mutations that occurred during embryonic development.
To distinguish between these possibilities, we analysed the mtDNA from lymphocytes of the parents and two children in each of two families registered with the CEPH (Centre d'É tude du Polymorphisme Humain). These analyses confirmed the conclusions made above in that heteroplasmic variants were observed in all except one sample (Supplementary Tables 3 and 4 ). In addition, they informed the interpretation of these heteroplasmies in the following ways.
First, paternal: there were 30 homoplasmic alleles in the fathers of these two families that were not found in their spouses (examples in Table 3 ; complete data in Supplementary Tables 3 and 4). None of LETTERS these variants were passed on to any of the four children. This excludes the possibility that the heteroplasmies observed in the progeny's cells were transmitted from sperm. Second, maternal: the results in Table 3 provide conclusive evidence that a portion of the heteroplasmy observed in the progeny was derived from the mother. Thus, the mother of CEPH family 1377 had two heteroplasmic variants, each present at about 56%, that were both passed on to both her children. Importantly, both these heteroplasmic variants were present in both children at the same allelic frequency (about 56%). These heteroplasmic variants were therefore unequivocally present in the maternal germ line as well as in her lymphoid cells. In the other kindred (CEPH family 45), there were three heteroplasmic variants in the mother, and none were passed on to the children. The fact that these were not inherited is consistent with a bottleneck during maternal germ-cell development thought to be responsible for the maintenance of homoplasmy in general. An alternative explanation is that the three maternal heteroplasmic variants were not present in the germ line of the mother of CEPH family 45 and instead were tissue-specific mutations confined to lymphocytes and other somatic cells. We favour this latter possibility for two reasons. First, it is consistent with the large amount of tissuespecific heteroplasmy documented in Table 2 and described in the following paragraph. Second, even with a severe bottleneck, it is unlikely that a heteroplasmic variant present in a majority of the alleles would be excluded by random segregation from two separate oocyte precursors. Note that one of the heteroplasmic variants was present in 78% of the maternal mtDNA copies in CEPH family 45 (Supplementary Table 3 ). Even if the postulated bottleneck stage contained only one mitochondrial genome, the probability that this allele would be excluded from two randomly chosen oocytes is less than 5% (calculated from binomial distribution).
Third, de novo: the results in Table 3 provide evidence that most of the heteroplasmic variants identified in lymphocytes arose during development. No variants were present in both children that were not present in one of the parents. In contrast, there were two or three variants in each child that were not present in the sibling or the parents. The allelic frequencies of these variants were as high as 36%. Although some of these variants may have arisen during expansion of the lymphoid cells in culture, it is notable that similar degrees of allelic variation in heteroplasmic variants were present in several tissues taken directly from patients without further culturing (Table 2 and Supplementary Table 2 ).
Thus, heteroplasmy was observed in nearly all of the normal tissues from the individuals examined in the current study (Tables 1-3 and  Supplementary Tables 1-4 ). Furthermore, the degree of heteroplasmy varied in a tissue-specific manner. These findings are consistent with previous observations of tissue-specific mtDNA deletions 17 and mtDNA mutations in human stem cells 18, 19 . A small fraction of the heteroplasmic variants were clearly inherited from the mother, but the remainder were apparently somatic mutations that probably occurred during very early embryonic development, as demonstrated by the fact that the same heteroplasmic variant was present in two different tissues (for example liver and kidney) but not in other tissues.
We next turned our attention to colorectal cancers arising from the colonic mucosae of the ten individuals described above (Supplementary Table 1 ). Each of the 279 homoplasmic alleles identified in the colonic mucosae were also found to be homoplasmic in the colorectal cancers from the respective patient. In addition, 90% of the cancers harboured at least one point mutation not present in the matched normal mucosa (Supplementary Tables 5 and 6 ). This result is consistent with previous studies documenting that somatic mutations of mtDNA are frequently found in human cancers [20] [21] [22] [23] . However, with the precise quantification achieved with deep sequencing, it was clear that most of these cancer-specific somatic mutations were heteroplasmic rather than homoplasmic. Indeed, of the 20 cancer-specific point mutations identified, only about 10% were homoplasmic (Supplementary Table 5 ).
A comparison between the heteroplasmic variants present in normal colonic mucosae with those in the cancers permitted us to test a model of mtDNA somatic mutation development proposed previously 24 , in which it was suggested that any heteroplasmic mutation present in a stem cell should become either homoplasmic or be lost within 70 generations, given reasonable estimates of mtDNA copy number and segregation patterns. As cancer cells evolve through hundreds of generations over decades 25 , we would expect that any heteroplasmic mutation in normal colorectal mucosa would not exist in the same heteroplasmic state in the cancer developing from it. Our results strongly support this model: of 41 heteroplasmic mutations in normal colorectal mucosae, 28 (68%) were absent from the cancer and 9 (22%) were present in the homoplasmic state (Supplementary Table 6 ).
With the use of similar reasoning, it was possible to determine the genealogy of individual mtDNA molecules during tumour progression in some cases. For example, in patient 7, the cancer-cell mtDNA underwent a bottleneck in which a single mtDNA molecule harbouring heteroplasmic variants at nucleotides 59 and 225 was eventually able to become the dominant mtDNA species in the cancer cell (Supplementary Table 6 ). Another mtDNA molecule present in 91.8% of the alleles of the normal mucosae was lost during this bottleneck or in subsequent cell divisions (Supplementary Table 6 ). Note that we cannot determine whether the bottleneck occurred during neoplastic development rather than in a normal colorectal epithelial stem cell from which the cancer developed. However, at some point later during tumour development, two other mutations, at nucleotides 1576 and 12009, arose. Given the relative frequencies of these two mutations (7.8% and 68.8% of the cancer alleles) it is reasonable to suggest that the mutation at nucleotide 12009 arose earlier than the mutation at nucleotide 1576. In both cases, an insufficient number of generations has passed to take these two variants to the homoplasmic state (or to oblivion). There were two differences between the somatic mutations identified in cancers and the heteroplasmic variants identified in normal tissues. First, 85% of the cancer-specific somatic mutations were in protein-coding or RNA-coding regions, whereas only 33% of the heteroplasmic variants were in protein-coding or RNA-coding regions (P 5 0.0005, Fisher's exact test). Second, only 15% of the cancer-specific somatic mutations were present in the mtDNA databases, whereas 75% of the heteroplasmic variants in normal tissues were present in these databases (P , 0.0001, Fisher's exact test). One interpretation of these data is that the process responsible for generating somatic mutations in tumours, whether due to exogenous or endogenous carcinogens, is different from that responsible for mutations during embryonic development (the period during which most heteroplasmic variants in normal tissues seem to be generated, as described above). Another interpretation is that a major fraction of the somatic mutations in cancers are intrinsically selected for their tumour-promoting effect rather than representing random segregation events such as those that presumably occur during embryogenesis. Yet a third possibility is that variants in protein-coding regions would have been selected against during organismal development but not during tumour development.
Somatic mutations provide exquisitely specific biomarkers for cancer diagnostics 26 . Somatic mutations in mitochondrial DNA are particularly well suited to such diagnostic applications because, when homoplasmic, they are 500-1,000-fold more numerous in the cell than nuclear DNA mutations 21, 23, 27 . We wondered whether heteroplasmic mutations could be identified in blood samples from cancer patients despite their relatively low representation compared with homoplasmic mutations. To test this idea, we studied the plasma of two colorectal cancer patients before and after surgery to remove their cancers ( Supplementary Fig. 4 ). In both patients, nuclear DNA mutations were evident in the plasma before surgery but not afterwards 28 . Mutant mtDNA template molecules were also identified in the plasma of these two patients at much higher concentrations before surgery than after it, confirming their tumour specificity. The concentration of mutant mtDNA molecules in the plasma greatly exceeded the concentration of the mutant nuclear genes, even though both mtDNA mutations were heteroplasmic. Accordingly, only 25 ml of plasma was required to detect the tumour-specific mtDNA mutations reliably, whereas at least 2 ml of plasma is generally required to search for nuclear DNA mutations 28 .
Because mtDNA template molecules are so numerous in comparison with nuclear DNA template molecules, they are also useful for forensic applications. Previous studies have shown variations in the length of mononucleotide tracts in mtDNA from hair roots compared with blood 29, 30 . Our new results clearly show that heteroplasmies affect the entire mitochondrial genome, are common in normal individuals and vary markedly from tissue to tissue. Thus an individual, and perhaps even a single cell, does not have a single mtDNA genotype. Instead, tissues have a mixture of genotypes, a few of which may be maternally inherited and the remaining ones the result of somatic mutations. This suggests caution in excluding identity on the basis of a single or small number of mismatched alleles when the tissue in evidence (such as sperm) is not the same as the reference tissue of the suspect (such as blood or hair).
METHODS SUMMARY
All samples were collected according to procedures approved by the Institutional Review Board of the Johns Hopkins Medical Institution. Mitochondrial DNA from total cellular DNA was enriched by PCR-based or capture-based strategies. In PCR-based enrichment, three sets of primers were designed to amplify amplicons that cover the mtDNA genome. Purified, blunt-ended PCR products were ligated to form high-molecular-mass DNA that was subsequently fragmented by sonication. Fragmented DNA was then end-repaired, A-tailed and ligated with a paired-end adaptor oligonucleotide from the Illumina genomic DNA library preparation kit in accordance with the manufacturer's instructions. Adaptor-ligated products were then size-selected by gel purification and amplified to obtained genomic DNA libraries that were suitable for the Illumina Genome Analyser.
For the capture-based approach, Illumina genomic DNA libraries were prepared from total cellular DNA. To capture mtDNA fragments, 50 biotinylated singlestrand DNA probes (baits) about 300-360 bases in size were prepared. These baits were then used for hybridization with the total cellular DNA-derived library. After two rounds of hybridization, the captured library DNA (enriched for mtDNA fragments) was amplified before analysis on the Illumina GAII. The 36 base tags obtained from sequencing were aligned to the human mtDNA sequence (NCBI entry NC_012920) with Eland software from Illumina. Tags that passed a set of filters were used for determining coverage and mutation analyses. Background mutation rates derived from PCR and sequencing was determined by sequencing PCR products amplified from nuclear DNA. The Mitomap (http://www.mitomap. org) and mtDB (http://www.genpat.uu.se/mtDB/) databases were used to identify sequence variants. Confirmation of a subset of variants (from both cancer cells and normal tissues) was performed by PCR amplification and conventional Sanger dye terminator sequencing. Detection of circulating mutant APC gene and mutant mtDNA in plasma by BEAMing was performed as described previously 28 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
PCR-based enrichment strategy. Total cellular DNA (3-6 ng, equivalent to about 500-1,000 cells) was used as a template for each PCR reaction. Amplicons generated with primer sets PCR1 and PCR2 ( Fig. 1a and Supplementary Table 7 ) were in general produced with HotStart Phusion polymerase (NEB) in reactions of 30 ml containing 1 3 Phusion HF buffer, 0.2 mM dNTPs, 0.5 mM forward primer and 0.5 mM reverse primer, 5% dimethylsulphoxide (DMSO) and 0.6 U of Phusion polymerase. The following cycling conditions were used: 1 cycle of 98 uC for 30 s; 25 cycles of 98 uC for 10 s, 60 uC for 30 s, and 72 uC for 30 s. Amplicons generated with primer set PCR3 ( Fig. 1a and described previously 15 ) were produced in the same fashion, with the exception that the 72 uC elongation step was for 90 s.
For each DNA sample, PCR products representing 25 amplicons (PCR1 or PCR2) or nine amplicons (PCR3) were pooled. PCR1 and PCR2 amplicons were purified with a kit from Agencourt (cat. no. 000130), and the longer PCR products generated with primer set PCR3 were purified with a kit from Omega Bio-Tek (cat. no. D2500-01). The pooled, purified PCR product (2-5 mg) was blunt-ended at 20 uC for 30 min in a total volume of 100 ml containing 1 3 T4 ligation buffer, 10 mM ATP, 1 mM of each dNTP, 5 ml of T4 DNA polymerase, 1 ml of Klenow polymerase and 5 ml of T4 PNK (all enzymes were obtained from NEB). Bluntended DNA was purified with a Qiagen PCR purification kit (cat. no. 28104) and ligated using Quick Ligase (NEB), in a total volume of 100 ml, as described by the manufacturer. Ligated DNA was purified with a Qiagen PCR purification kit (cat. no. 28104) and eluted with 100 ml of 70 uC elution buffer. Purified, ligated DNA was fragmented with a Bioruptor sonicator (Diagenode) at low power, by cycling for 15 s on, then 15 s off, for 2 3 15 min while being cooled in an ice bath. This sonication reduced the size of the ligated DNA from more than 12 kilobases to 100-400 bp. The fragmented DNA was purified and used for preparation of an Illumina DNA library as described in the Illumina genomic DNA library preparation manual. Capture-based enrichment strategy.
Step 1: preparation of probes. Fifty amplicons were designed to cover the mtDNA genome (Supplementary Table 8 ). For every amplicon, the 59 end of the forward primer was tagged with M13-Forward sequence (59-gtaaaacgacggccagt-39). PCR was performed as described above, with normal human colon mucosa DNA as the template and primers without the biotin tag. These PCR products were then used as templates for a second PCR with doublebiotinylated M13-Forward sequence as forward primers ( Supplementary Table 7 ) to obtain biotinylated PCR products. The resultant PCR products were pooled and purified with a Qiagen kit (cat. no. 28104). The purified PCR products were then mixed with an equal volume of 2 3 bind-and-wash buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA, 2 M NaCl) containing 250 ml of Dynal MyOne streptavidin-coated beads (product no. 650.02; Invitrogen). After incubation at 23 uC for 1 h, the beads were washed twice with 1 3 PCR buffer (20 mM Tris-HCl pH 8.4, 50 mM KCl). Bead-attached DNA was then denatured in 0.2 M NaOH for 5 min at room temperature to remove the non-biotinylated strands, and washed in 1 3 PCR buffer. The biotinylated single-stranded DNA (ssDNA) remaining attached to the beads was released by incubation in 200 ml of Hi-Di formamide (product no. 4311320; ABI) at 95 uC for 3 min. ssDNA probe mixture was precipitated by adding 3 M sodium acetate pH 5.2, DNA carrier and 2.5 volumes of ethanol, then centrifuged for 5 min in a Microfuge at about 12,000g. After the pellet had been washed with 75% ethanol, the ssDNA was resuspended in water.
Step 2: hybrizidation-based capture. Total cellular DNA was used to prepare a paired-end library by slight modifications of the standard Illumina protocol. Library DNA (2.5 mg) was then mixed with 2.5 mg of the single-stranded biotinylated DNA in 50 ml containing 0.2% SDS and 4.5 3 SSPE (1 3 SSPE: 0.15 M NaCl, 0.01 M NaH 2 PO 4 , 0.001 M EDTA; Amresco), covered with mineral oil and incubated at 95 uC for 3 min, followed by incubation at 65 uC for 12 h to allow hybridization. DNA was then purified with NucleoSpin Extract II with NTB buffer (Clontech). The DNA was eluted from the NucleoSpin column in 100 ml of elution buffer and was captured on streptavidin-coated MyOne beads as described above. The beads were washed twice with 1 3 PCR buffer, resuspended in washing buffer composed of 0.1% SDS in 2 3 SSPE, and incubated for 30 min at 68 uC, with shaking. The beads were collected on a magnet and washed with fresh washing buffer for a further 30 min at 68 uC, then washed twice with 1 3 PCR buffer. The captured target DNA was released by denaturation in 0.2 M NaOH at room temperature for 5 min, ethanol-precipitated as described above, then resuspended in 15 ml of elution buffer (5 mM Tris-HCl pH 8.5). A 2-ml portion was used as template for HotStart Phusion PCR (18-cycle) amplification to obtain a first-round-enriched mtDNA library. About 3 mg of first-roundenriched mtDNA library DNA was then mixed with 2.5 mg of the biotinylated ssDNA described above in 110 ml of 1 3 PCR buffer (from 10 3 PCR buffer, cat. no. 53286; Invitrogen). Hybridization was performed by incubating the DNA at 95 uC for 1 min; it was then cooled to 50 uC at 0.1 uC s 21 , then incubated at 50 uC for 1 min. The hybrids were captured with MyOne beads, washed once in 1 3 PCR buffer and then twice with wash solution I (2 3 SSC, 0.05% SDS), using a 15-min incubation at room temperature for each wash; beads were then washed twice, for 15 min each, with wash solution II (0.1 3 SSC, 0.1% SDS) at 50 uC, then once with 1 3 PCR buffer. Captured target DNA was released and ethanolpurified as described above, resuspended in 15 ml of elution buffer (5 mM Tris-HCl, pH 8.5). Of this, 3 ml was used as a template for HotStart Phusion PCR (18-cycle) amplification to obtain a second-round-enriched mtDNA library, which was subsequently used for sequencing with a Genome Analyser II instrument. Genome Analyser sequence data analysis. The 36 base tags obtained from the Genome Analyser II reads were aligned to the human mtDNA sequence of 16,569 bp (NC_012920) using Eland software from Illumina. This alignment allowed up to two mismatches at the first 32 out of the total 36 bases in each tag. Four bases in the human mtDNA genome were excluded from analysis: bases 309-311 (in a long stretch of 'Cs') and base 3107 ('N' base in NC_012920). Three quality filters were used for selecting tags for further analysis: first, all 36 bases in a tag were required to have a Phred score of at least 23 (meaning there was about 0.5% probability of a base-calling error); second, no 'N' base was allowed anywhere in the 36 bases; and third, not more than three mismatches were permitted in the 36 bases (for example, the last four bases could have no more than two mismatches if there was one mismatch in the first 32 bases). Subsequent analysis was performed with database software SQL 2005. Each position of the mtDNA genome was assigned a coverage depth, representing the number of times the position was sequenced. To determine this, only sequences that passed quality filters, rather than raw sequences, were taken into consideration. The mutation fraction represents the fraction of tags containing that base in mutant form. To be categorized as a mutation, the identical mutation had to be identified, first, in at least ten 'distinct' tags-that is, tags whose first base was at ten different positions (for clarity, there are 16,569 distinct tags possible in the mitochondrial genome)-and second, in at least three tags sequenced from the forward direction and at least three from the reverse direction. These criteria were applied to normal mucosa samples, cancer samples and samples from CEPH families. For analysis of mtDNA from normal human organs, mutations were defined by at least five 'distinct' tags, and also at least one tag sequenced from the forward direction and at least one from the reverse direction. Determination of background error rates. PCR products used for Genome Analyser II sequencing were generated through two PCR steps. In the first step, 96 pairs of PCR primers, each with a universal tag (59-ACACGACGCTCTT CCGATCT-39 for forward primers, 59-GCATACGAGCTCTTCCGATCT-39 for reverse primers), were designed to amplify 96 different regions on chromosomes 13, 18 and 21. Genomic DNA from human B lymphoblastoid cells was used as PCR template. After 30 cycles of PCR using Phusion high-fidelity polymerase (NEB), the PCR product was mixed and diluted 1:1,000 in TE buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA). In the second PCR step, one pair of PCR primers were designed to contain the universal sequence used in the first step and the Illumina grafting primers (forward primer, 59-AATGATACGGCGACCA CCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT-39; reverse primer, 59-CAAGCAGAAGACGGCATACGAGCTCTTCCGATCT-39). The PCR was conducted in a single PCR tube with this pair of primers and the diluted PCR product mixture from first step as template. After 15 cycles of PCR with Phusion Flash master mix (NEB), the product was purified with a Qiaquick purification column (cat. no. 28104; Qiagen) and quantified by absorption at 260 nm.
For sequencing data analysis, a Phred score of at least 23 for each base in the 36-base tags was applied to select high-quality tags for mutation analysis. For every non-heterozygous position, coverage of the non-reference base and reference base was extracted from the sequencing result. The sequencing error for each base was calculated as the coverage of the non-referenced base divided by the coverage of the reference base. Analysis of 2,746 bases by two independent experiments showed that the average fractions of mutations per base were 0.063% and 0.052%, with a standard deviation of 0.058% in both experiments, and the highest mutation rates were 0.82% and 0.7%, respectively. Sanger sequencing and BEAMing confirmation of mutation. Total cellular DNA (3-6 ng) was used as a template for each PCR reaction with HotStart Phusion polymerase (NEB) in reactions of 30 ml containing 1 3 Phusion HF buffer, 0.2 mM dNTPs, 0.5 mM forward primer and 0.5 mM reverse primer, 5% DMSO and 0.6 U of Phusion polymerase. The following cycling conditions were used: 1 cycle of 98 uC for 30 s; 25 cycles of 98 uC for 10 s, 60 uC for 30 s, 72 uC for 30 s. PCR products were purified with PCR purification kit (cat. no. 28104; Qiagen), and conventional dye terminator sequencing with forward and reverse PCR primers was performed by MWG biotech. BEAMing confirmation of mutation was performed as described previously 28 . Detection of circulating mutant mtDNA in plasma. Collection of plasma samples from colorectal cancer patients and isolation of circulating DNA was performed as described previously, with modifications 28 . Specifically, we used a
